A combination of CBD and THC rapidly and significantly reduces agitation in hospice-eligible people with dementia, suggest top-line results from the phase 2 LiBBY (Life’s End Benefits of cannaBidiol and tetrahYdrocannabinol) clinical trial. The findings were reported for the first time at the Alzheimer’s Association International Conference 2026 in London and online.
This article was originally published on MedicalXpress.com

